Episode 39
Jeremy Levin, Bruce Booth, Rob Perez, Dawn Bell and Ethan Perlstein join Daphne and Josh to discuss the macro biotech picture, recap the recent Jefferies Conference, discuss the impact of partisanship in healthcare legislation (including IRA), the coming impact for private and crossover investors, the Acrivon Therapeutics IPO & other recent financings, the Editas clinical setback and some recent FDA approvals, and the a16z story about the biggest company in the world being a consumer health tech company. The group also debates what makes a great biotech CEO and how those CEOs should handle company setbacks.
Community of experts and insiders joining Biotech Hangout (formerly known as Biotech Clubhouse) include Daphne Zohar, Josh Schimmer, Bruce Booth, Tim Opler, Chris Garabedian, Michal Preminger, Dawn Bell, Rob Perez, Otello Stampacchia and more.
Available Results
Generated results are saved to the knowledge database for reuse and search.
Extract Knowledge
Pick what you want extracted first. Model, scope, and chapter options appear after a template is selected.